• About us
• Contact

Advertisement

Organisation › Details

Oncologie Inc. (US/CN)

OncXerna is a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates. OncXerna is working to expand next-generation precision medicine to a larger group of cancer patients by leveraging the company’s Xerna™ platform to prospectively identify patients based on the dominant biology of their cancer. OncXerna’s approach pairs those patients with OncXerna’s clinical-stage therapeutic candidates and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes. The Xerna™ TME Panel uses proprietary RNA-based gene expression data and a machine learning-based algorithm to classify patients based on the interplay between angiogenic and immunogenic dominant biologies of the tumor microenvironment (TME), and has been developed as a clinical assay. The Xerna™ TME Panel is an investigational assay that has not been approved, and has not been demonstrated to be safe or effective for any use. *

 

	Start	2018-02-13 existent
	End	2020-09-18 renamed
	Today	OncXerna Therapeutics Inc.
	Successor	OncXerna Therapeutics Inc.
	Industry	drug development
	Industry 2	cancer drug
	Person	Benjamin, Laura (Oncologie Inc 201802 CEO)
	City	n. a. Boston, MA
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Qiagen N.V.. (8/9/21). "Press Release: Qiagen and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements". Hilden, Waltham, MA & Germantown, MD.
		Record changed: 2023-07-10

Advertisement

More documents for Oncologie Inc. (US/CN)

• [1] Mologen AG. (11/16/18). "Press Release: Mologen AG to Retain Rights to Lefitolimod – Termination of Negotiations with Oncologie Inc. and Assessment of All Strategic Options in the Light of a Likely Read-out of the Pivotal Phase III IMPALA Trial in 2019"...
• [2] Mologen AG. (11/8/18). "Press Release: Implementation of Financing Measures and Publication of Study Results". Berlin....
• [3] Mologen AG. (8/16/18). "Press Release: Mologen and Oncologie. Global Assignment and Co-development Agreement Relating to Mologen’s Lead Compound Lefitolimod". Berlin....
• [4] Mologen AG. (8/9/18). "Press Release: Mologen AG with Positive Developments in the First Half of 2018. Successful Financing Measures and Continuation of Clinical Studies"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.